Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK — 881 in Primary Immunodeficiency Disease (PID) at ESID 2026
For best results when printing this announcement, please click on link below: Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 − TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patie